Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Low PSA (prostate specific antigen) score can predict cancer return after radiation:

This article was originally published in Clinica

Executive Summary

Individuals with a low prostate specific antigen (PSA) score are less prone to the disease, but new research has suggested that a low PSA score after radiation therapy in prostate cancer patients may predict the likelihood of whether cancer will return in the prostate or elsewhere. The study was published in the International Journal of Radiation Oncology*Biology*Physics (March 15). "These findings may help us to identify high-risk patients early. This will allow doctors to consider other adjuvant or salvage therapies to hopefully increase their chances for survival," commented Michael Ray, lead author of the study.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel